Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chromadex Corp CS
(NQ:
CDXC
)
3.300
-0.180 (-5.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Chromadex Corp CS
< Previous
1
2
3
4
5
Next >
Recap: ChromaDex Q1 Earnings
May 12, 2022
ChromaDex (NASDAQ:CDXC) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex missed estimated earnings...
Via
Benzinga
ChromaDex Corporation Reports First Quarter 2022 Financial Results
May 12, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 29, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
April 22, 2022
From
ChromaDex Corporation
Via
Business Wire
Recap: ChromaDex Q4 Earnings
March 09, 2022
ChromaDex (NASDAQ:CDXC) reported its Q4 earnings results on Wednesday, March 9, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex...
Via
Benzinga
Recap: ChromaDex Q3 Earnings
November 03, 2021
ChromaDex (NASDAQ:CDXC) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:02 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
April 14, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
April 06, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
March 16, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
February 22, 2022
From
ChromaDex Corporation
Via
Business Wire
Earnings Scheduled For March 9, 2022
March 09, 2022
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
March 08, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth...
Via
Benzinga
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
February 09, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
January 31, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
January 25, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements
January 20, 2022
ChromaDex Corp (NASDAQ:CDXC) has
Via
Benzinga
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
January 20, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation (CDXC) Q3 2021 Earnings Call Transcript
November 04, 2021
CDXC earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
November 03, 2021
From
ChromaDex Corporation
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
January 07, 2022
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap...
Via
Benzinga
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
October 18, 2021
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
October 13, 2021
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
October 01, 2021
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
September 29, 2021
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
September 20, 2021
From
ChromaDex Corporation.
Via
Business Wire
Why ChromaDex Stock Is Sinking Today
September 15, 2021
The company lost a key patent infringement lawsuit but plans to appeal the court decision.
Via
The Motley Fool
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Why Are ChromaDex Shares Trading Lower On Wednesday?
September 15, 2021
ChromaDex Corp (NASDAQ: CDXC) dropped over 20% during the premarket despite its announcement over plans to appeal a court ruling issued by the U.S. District Court...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 15, 2021
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares increased by 68.88% to $11.94 during Wednesday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
September 15, 2021
From
ChromaDex Corporation
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 10, 2021
Gainers IVERIC bio (NASDAQ:ISEE) stock increased by 65.36% to $14.37 during Friday's pre-market session. The company's market cap stands at $1.4 billion. T2...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.